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Abstract
Aims/hypothesis The transcription factor 7-like 2 (TCF7L2)
rs7903146 T allele associates with type 2 diabetes in several
populations, possibly mediated via decreased incretin
secretion and/or action and altered beta and alpha cell
function. We aimed to study circulating levels of glucose,
proinsulin, insulin, C-peptide, glucagon, glucagon-like
peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) and
gastric inhibitory polypeptide (GIP) among individuals
carrying the high-risk rs7903146 TT genotype and low-
risk CC genotype following a meal test.
Methods A meal challenge was performed in 31 glucose-
tolerant men (age 54±7 years and BMI 26±3 kg/m2) with
rs7903146 TT genotype and 31 glucose-tolerant age- and
BMI-matched men with CC genotype (age 53±6 years and
BMI 26±3 kg/m2). Serum proinsulin, insulin, C-peptide
and plasma glucose, glucagon, GLP-1, GLP-2 and GIP
were obtained 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150,
180, 210, and 240 min after ingestion of a standardised
breakfast meal.
Results An elevated incremental AUC for plasma glucose
was observed among TT genotype carriers (CC carriers
21.8±101.9 mmol/l×min vs TT carriers 97.9±89.2 mmol/
l×min, p=0.001). TT carriers also had increased AUCs for
proinsulin (CC carriers 6,030±3,001 pmol/l×min vs TT
carriers 6,917±4,820 pmol/l×min, p=0.03), C-peptide (CC
carriers 397.6±131.9 nmol/l×min vs TT carriers 417.1±
109.3 nmol/l×min, p=0.04) and GIP (CC carriers 12,310±
3,840 pmol/l×min vs TT carriers 14,590±5,910 pmol/l×
min, p=0.004).
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Conclusions/interpretation Middle-aged normoglycaemic
individuals carrying the rs7903146 TCF7L2 risk TT
genotype show early signs of dysregulated glucose metab-
olism, decreased processing of proinsulin and elevated GIP
secretion following a meal challenge.
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Abbreviations
GIP Gastric inhibitory polypeptide
GIP-R Gastric inhibitory polypeptide receptor
GLP Glucagon-like peptide
GLP-1R Glucagon-like peptide-1 receptor
HOMA-IR HOMA-insulin resistance
IAUC Incremental AUC
ISR Insulin secretion rate
TCF7L2 Transcription factor 7-like 2
Introduction
Type 2 diabetes mellitus is a complex disease that results
from the interplay between adverse health behaviour and
genetic risk factors [1]. More than 20 validated common
type 2 diabetes susceptibility loci have been identified, of
which the majority have been shown to associate with
pancreatic islet cell dysfunction, insulin resistance or
obesity [2–7]. The rs7903146 transcription factor 7-like 2
(TCF7L2) T allele has shown the strongest association with
type 2 diabetes to date, with a per allele odds ratio of 1.4
[8]. However, despite major efforts to elucidate the
underlying mechanisms whereby this variant increases the
risk of type 2 diabetes, its functional impact and its specific
role in disease pathogenesis are still unclear.
TCF7L2 spans a ~216 kb region on chromosome 10, and
consists of 17 exons [9, 10]. Tissue-specific splicing
patterns have been identified; the pancreatic islet and colon
display a unique splice isoform containing exons 4 and 15
[10, 11]. Rs7903146 is located between exons 4 and 5, and
may influence the splicing pattern of TCF7L2 [10].
TCF7L2 is a transcription factor that is part of the Wnt/
β-catenin signalling pathway. This is a ubiquitous signal-
ling pathway that ultimately activates transcriptional pro-
grammes. Thus, Wnt signalling may promote mechanisms
such as cell proliferation, tissue expansion and differenti-
ation [12].
As a consequence of the central function of TCF7L2,
several mechanisms have been suggested to explain the
effect of variants in TCF7L2 on the development of type 2
diabetes. One hypothesis is based on the involvement of
TCF7L2 in the gut L and K cells in the transcription ofGCG,
encoding glucagon-like peptide-1 (GLP-1), [13] and of GIP
[14], respectively, connecting TCF7L2 to the entero-insular
axis and GCG transcription in alpha cells encoding
glucagon [15]. Patients with type 2 diabetes have impaired
insulin responses following a meal or an oral glucose
stimulus and defective incretin secretion has been shown to
contribute to this [16]. It has, however, also been suggested
that a defect in glucose sensing of the beta cell could impair
glucose-mediated insulin secretion, possibly leading to
increased glucagon levels [17].
However, previous studies have failed to detect reduced
secretion of GLP-1 following an oral glucose load in T allele
carriers of the TCF7L2 rs7903146 variant [18–20], and an
increased level of glucagon [21].
A second hypothesis is based on in silico analysis
suggesting that the rs7903146 T allele of TCF7L2 might act
through decreased transcription of PCSK1 and PCSK2 [22].
These genes encode convertases involved in the processing
of GLP-1, GLP-2 and gastric inhibitory polypeptide (GIP)
in the intestinal L and K cells, and of glucagon in the alpha
cells and proinsulin in the beta cells of the pancreas. In
support of the latter hypothesis, several studies have shown
increased proinsulin levels as well as increased proinsulin/
insulin ratios in TCF7L2 risk allele carriers [22–26].
An additional hypothesis is based on the finding that
pancreatic islets from type 2 diabetic patients had a lower
levels of glucagon-like peptide-1 receptor (GLP-1R) and
gastric inhibitory polypeptide receptor (GIP-R) and did not
contain detectable amounts of TCF7L2 protein by immuno-
fluorescence staining. Furthermore, downregulation of
GLP-1R and GIP-R was seen after treatment with small
interfering TCF7L2 in isolated human pancreatic islets [27].
Several studies have observed impaired GLP-1-induced
insulin secretion [19, 21] and a diminished incretin effect
among rs7903146 T allele carriers [28] without identifying
reduced levels of GLP-1 and GIP [18], supporting the
existence of a defect in the transcription of incretin receptors
leaving the beta cell resistant to incretin hormones.
In contrast, other studies have reported islet-specific
upregulation of TCF7L2 [29] and increased levels of
TCF7L2 mRNA [28] in type 2 diabetic patients. The latter
study also found a positive correlation between the mRNA
levels of TCF7L2 and the insulin gene; however, in this
study a lower in vitro glucose-stimulated insulin release
was found, suggesting that TCF7L2 influences post-
transcriptional events of insulin production [28]. Thus,
despite the intensive investigation of the actions whereby
variants within TCF7L2 increase the risk of type 2 diabetes,
the pathogenetic contribution of this locus to increased
type 2 diabetes risk is far from clear.
The aim of this study was to examine the impact of the
TCF7L2 rs7903146 on incretin secretion, incretin action
and insulin secretion following a standardised meal challenge
test in white healthy adults with TCF7L2 rs7903146 low-risk
CC and high-risk TT genotypes, respectively.
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Methods
Study participants This study was carried out in 62 men
recruited from the Inter99 population-based study [30].
Thirty-one were homozygous for the TCF7L2 rs7903146
high-risk T allele and 31 were age- and BMI-matched
individuals, homozygous for the low-risk TCF7L2 C allele
(Table 1). They were all glucose tolerant following a
standard OGTT when examined in the Inter99 study 7 and
2 years prior to participation in the present study. All
individuals agreed to participate and gave oral and written
consent. The study was approved by the Copenhagen
County Ethical Committee and was conducted according
to the principles of the Helsinki Declaration.
Genotyping Genotyping of TCF7L2 rs7903146 was per-
formed in duplicate in all participants as previously
described by Helgason and colleagues [8] and by Rung
and colleagues [7]. No mismatches were observed.
Standardised meal challenge The participants consumed a
test meal consisting of 50 g white bread, 50 g black bread,
10 g butter, 40 g cheese, 20 g sugar-free jam and 200 ml
milk (34% fat, 47% carbohydrate, 19% protein), comprising
a total of 2,370 kJ (566 kcal). The meal was consumed within
15 min. Arterialised venous blood was drawn 20, 10 and
0 min before and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150,
180, 210 and 240 min after ingestion of the meal. Blood was
sampled into fluoride tubes for plasma glucose analysis and
into tubes containing heparin or EDTA (6 pmol/l) plus
aprotinin (500 kallikrein inhibitor units/ml blood; Trasylol,
Bayer, Leverkusen, Germany) and a specific dipeptidyl
peptidase-4 inhibitor (valine-pyrrolidide, 0.01 mmol/l final
concentration; Novo Nordisk, Bagsværd, Denmark) for
hormone analysis.
Biochemical analyses Blood samples were drawn after a
12 h overnight fast. Plasma glucose was analysed by a
glucose oxidase method (Granutest, Merck, Darmstadt,
Germany) with a detection limit of 0.11 mmol/l and intra-
and interassay coefficients of variation of <0.8 and <1.4%,
respectively. Serum C-peptide was measured using a
time-resolved fluoroimmunoassay with the AutoDELFIA
C-peptide kit, having a detection limit of 5 pmol/l and
intra- and interassay coefficients of variation of <4.7%
and <6.4%, respectively. Serum insulin (excluding des
[31, 32] and intact proinsulin) was measured using the
AutoDELFIA insulin kit (Perkin-Elmer, Wallac, Turku,
Finland) with a detection limit of 3 pmol/l and with intra-
and interassay coefficients of variation of <3.2% and
<4.5%, respectively. Proinsulin was measured using a
sandwich ELISA that measures intact proinsulin as well as
the four metabolites: split(32-33), des(31,32), split(65-66)
and des(64,65)-proinsulin. The detection limit is 0.3 pmol/l
and intra- and interassay coefficients of variation are
<6.2% and <8.7%, respectively. This assay has no cross-
reactivity with insulin, C-peptide, IGF-I or IGF-II. Total
plasma COOH-terminal amidated GLP-1 was assayed by
radioimmunoassay using polyclonal antiserum 89390
(raised in rabbits). This antibody has an absolute require-
ment for the amidated C-terminus of GLP-1, and thus does
not cross-react with C-terminally truncated metabolites or
with glycine-extended forms; it therefore mainly reacts with
GLP-1 of intestinal origin. The assay has a detection limit of
~1 pmol/l and an ED50 of 25 pmol/l. Intra- and interassay
coefficients of variation are <6% and <15%, respectively
[31]. Plasma levels of intact (NH2-terminal) GIP were
assayed by radioimmunoassay using polyclonal antiserum
98171 (raised in rabbits) that is NH2-terminally directed and
does not recognise NH2-terminally truncated peptides. The
detection limit is <5 pmol/l with an ED50 of 48 pmol/l, and
intra- and interassay coefficients of variation were <6%
and <15%, respectively [32]. Plasma GLP-2 was measured
by radioimmunoassay employing antiserum 92160 and
standards of human GLP-2 (proglucagon 126–158, Novo
Nordisk, Bagsværd, Denmark) and monoiodinated Tyr-12
GLP-2, specific activity >70 MBq/nmol. The antiserum was
directed against the N-terminus of GLP-2 and therefore
measures only fully processed active GLP-2 of intestinal
origin [33]. The plasma glucagon radioimmunoassay was
directed against the C-terminus of the glucagon molecule
(antibody 4305) and therefore mainly measures glucagon of
pancreatic origin [34].
Statistical analyses A paired t test was applied to test for
differences between genotype pairs. For these analyses
measures of serum insulin were logarithmically transformed
prior to analysis. A linear regression model was applied in
order to perform analyses adjusted for fasting plasma
glucose, age and BMI. In the linear regression model
measures of serum insulin were log-transformed prior to
Table 1 Anthropometric and biochemical description of 62 individuals
included according to TCF7L2 rs7903146 CC and TT genotype
Characteristic CC TT p value
Age (years) 53.6±6.9 53.3±6.3 0.7
Weight (kg) 85.0±11.9 84.6±10.1 0.9
Height (cm) 180±6.1 182±7.9 0.3
BMI (kg/m2) 26.3±3.1 25.7±2.5 0.09
Waist (cm) 95.8±7.2 96.2±7.8 0.9
Waist–hip ratio 0.9±0.04 0.9±0.1 1.0
HOMA-IR 9.9±6.1 9.6±6.2 1.0
Data are means ± SD
p values were calculated using a paired t test
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analysis. A p value of less than 0.05 was considered
statistically significant.
Statistical power The sample size determination is based
on a two-sample two-sided t test at 5% significance level. A
total of 2×30 participants will provide a power of 90%
power to detect a difference of 280 pmol/kg (about 24%) in
AUC for insulin secretion rate (ISR) between the two
groups by the use of a paired t test. By using a regression
model we have a power of 90% power to detect an allele-
specific difference of 55% when estimated by the previ-
ously described method for calculating power [5]. This
corresponds to a difference of 57 mmol/l×min AUC for
glucose, 2,203 pmol/l×min AUC for proinsulin,
66,294 pmol/l×min AUC for C-peptide, 2,799 pmol/l×min
AUC for GIP, 1,425 pmol/l×min AUC for GLP-1,
795 pmol/l×min AUC for GLP-2 and 639 ng/l×min AUC
for glucagon between the two groups.
Calculations of physiological measures The AUCs were
calculated by the trapezoidal method, and incremental
AUCs (IAUCs) were calculated by subtraction of the
fasting values. ISRs (pmol kg−1 min−1) were estimated
from measured serum C-peptide concentrations using
deconvolution [35]. This mathematical operation calculates
the secretion rate based on pre-defined C-peptide kinetic
parameters from each individual’s weight, height, age, sex
and clinical status (glucose tolerance and obesity status)
determined in a population-based study [35, 36]. The
software ISEC, which implements all these factors [37],
was applied for the present study.
Results
The study was performed in a matched design where
TCF7L2 rs7903146 CC allele carriers were selected in
order to match TT allele carriers for age and BMI. The two
groups were similar in relation to measures of age, body
composition and HOMA-insulin resistance (IR; Table 1).
Levels of plasma glucose, serum insulin, serum pro-
insulin, serum C-peptide, plasma glucagon, intact plasma
GIP, total plasma GLP-1 and plasma GLP-2 during a meal
test were compared between the CC group and the TT
group (Fig. 1 and Electronic supplementary material [ESM]
Fig. 1). Preprandial fasting measures of plasma glucose
were found to be significantly lower among the TT carriers,
with inter-pair differences of 0.31 mmol/l (95% CI 0.13–
0.50 mmol/l) as well as levels at 15, 30 and 240 min
postprandially with inter-pair differences of 0.36 mmol l−1
(95% CI 0.08–0.6), 0.60 mmol/l (95% CI 0.2–1.05) and
0.17 mmol/l (95% CI 0.02–0.3), respectively. In contrast,
significantly higher levels of GLP-2 were observed at
20 min preprandial (inter-pair difference 5.6 pmol/l [95% CI
2.3–8.9]) and 10 min preprandial (inter-pair difference
4.8 pmol/l [95% CI 1.22–8.46]) among TT allele carriers. In
addition, postprandial plasma GLP-2 at 60 min (inter-pair
difference 4.6 pmol/l [95% CI 0.02–9.3]) was significantly
elevated among TT carriers. None of the remaining measures
of glucose homeostasis was significantly different using a t test.
Also fasting levels of total plasma cholesterol, plasma
triacylglycerols, plasma HDL-cholesterol, plasma LDL-
cholesterol and plasma VLDL-cholesterol were investigated;
however, we did not find any significant differences in these
lipids between the two groups.
As the fasting plasma glucose level among T allele
carriers was significantly lower than that in CC allele
carriers, we performed linear regression, adjusting for
fasting plasma glucose as well as age and BMI. Adjusting
for this confounder resulted in the detection of significantly
higher preprandial levels of serum proinsulin, serum C-
peptide, plasma GIP and plasma GLP-2 among carriers of
the risk allele (Fig. 1 and ESM Fig. 1). However, all analyses
were also performed including adjustments for HOMA-IR,
which resulted in the associations with proinsulin and C-
peptide disappearing even though the variant did not
significantly affect this estimate of insulin resistance.
Furthermore, postprandial levels of plasma glucose,
serum proinsulin, serum C-peptide and plasma GIP were
significantly elevated among TT homozygous individuals
(Fig. 1 and ESM Fig. 1).
The AUC and IAUC for glucose, insulin, proinsulin, C-
peptide, glucagon, GIP, GLP-1 and GLP-2 were calculated
(Table 2). TT carriers had a significantly higher IAUC and
AUC for glucose, AUC and IAUC for GIP, AUC and IAUC
for proinsulin and AUC for C-peptide compared with CC
carriers (Table 2).
One way of assessing whether incomplete processing of
proinsulin could be involved in disease pathogenesis is to
examine differences in proinsulin AUC/insulin AUC ratios
between the two groups. However, we did not observe any
significant difference (Table 2).
ISRs were calculated. Fasting levels of ISR were signifi-
cantly elevated among carriers of the TT genotype as well as
levels at 90 and 105 min postprandially. However, we did not
find any genotypic influence on AUC or IAUC for the ISR.
Discussion
Carriers of the rs7903146 TCF7L2 diabetes risk T allele
present an increased IAUC for plasma glucose in spite of a
significantly lower fasting plasma glucose level among
these individuals. Additionally, we found that the AUCs for
circulating levels of proinsulin, C-peptide and GIP following
a meal challenge were increased in the risk T allele carriers.
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However, the association with C-peptide was not consistent;
thus, the nominally significant association may be a chance
finding.
It was unexpected that we observed a decrease in fasting
plasma glucose level among TT genotype carriers. This
finding may be due to the design of the study, whereby
middle-aged glucose-tolerant TT genotype men, who may
have compensatory mechanisms that decrease their risk of
developing type 2 diabetes, were studied. If individuals with
impaired glucose regulation or overt type 2 diabetes had
been included in the study, it is possible that a more obvious
beta cell secretory defect may have been unmasked. The
present study also only included men, and we may have had
a different outcome had the study also included women.
Previous studies have reported either no association
between variants in TCF7L2 and impaired insulin sensitivity
[21, 38–43] or an association with increased insulin
sensitivity [19, 44]. Thus, the elevated plasma glucose
levels in the postprandial state are not likely to be due to
impaired insulin action in the peripheral tissues. Therefore,
we hypothesise that the elevated postprandial glycaemia is
mediated by an impaired pancreatic beta cell function.
In line with previous studies [19, 22], the linear
regression modelling revealed significantly elevated serum
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Fig. 1 Measures of plasma
glucose (a), serum proinsulin
(b), serum C-peptide (c), serum
insulin (d), plasma GIP (e), and
plasma GLP-1 (f) in 62 carriers
of TCF7L2 rs7903146 CC and
TT genotypes, respectively, who
underwent a standardised meal
test. *p<0.05 and **p<0.01
obtained from a paired t test;
†p<0.05 and ††p<0.01 obtained
from a linear regression model.
Red line, TT genotype carriers;
black line, CC genotype carriers
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proinsulin levels during the meal test. Yet we did not see
any significant differences in insulin levels, insulin/pro-
insulin ratio or proinsulin when we adjusted for HOMA-IR.
Therefore, this may suggest that the rs7903146 T allele of
TCF7L2 partly acts through decreased transcription of
PCSK1 and PCSK2 and thereby via decreased processing
of key hormones in glucose metabolism [22]. However, this
association may also be a result of increased insulin
secretion which, as previously mentioned, may be a
consequence of including only glucose-tolerant individuals.
We did not find significantly reduced levels of plasma
GLP-1, GLP-2 or GIP during the standardised meal test in
carriers of the risk T allele. These findings are also in line
with previous studies [20, 21, 28]. In fact, in the fasting
state, we observed an increase in the plasma levels of GLP-
2 (p=0.02). GLP-2 is expressed in equimolar ratios with
GLP-1 in entero-endocrine cells, yet GLP-2 is not known to
possess major insulinotropic effects [45]. Rather, GLP-2
has glucagonotropic effects [45] and has effects on nutrient
absorption and intestinal mucosal functionality [46]. Thus,
there is no clear relationship between the observed decrease
in fasting glucose and the increased GLP-2 in the fasting
state.
Increased levels of plasma GIP during the meal test were
seen among TCF7L2 TT carriers. This may be an adaptive
response, possibly to overcome a reduction in GIP-R
Table 2 AUC results for 62 carriers of the TCF7L2 rs7903146 CC or TT genotype who underwent a standardised meal test
Variable CC genotype TT genotype p value (pair test) p value (linear regression)a
AUC glucose (mmol/l×min)
AUC glucose 240 min 1,403±110 1,403±100 1.0 0.04
IAUC glucose 240 min 21.8±101.9 97.9±89.2 0.001 0.04
AUC insulin (pmol/l×min)
AUC insulin 240 minb 36,401±19,655 35,713±19,855 0.9 0.2
IAUC insulin 240 minb 27,252±14,943 26,222±15,308 0.8 0.4
AUC C-peptide (pmol/l×min)
AUC C-peptide 240 min 397,604±131,923 417,140±109,276 0.5 0.04
IAUC C-peptide 240 min 239,021±68,736 244,967±64,925 0.7 0.2
AUC proinsulin (pmol/l×min)
AUC proinsulin 240 min 6,033±3,001 6,917±4,820 0.4 0.03
IAUC proinsulin 240 min 4,085±1,961 4,805±3,682 0.3 0.05
AUC glucagon (ng/l×min)
AUC glucagon 240 min 2,598±1,116 2,336±1,208 0.2 0.7
IAUC glucagon 240 min 906±723 640±615 0.1 0.2
AUC GLP-1 (pmol/l×min)
AUC GLP-1 240 min 7,978±3,039 7,733±2,092 0.6 0.9
IAUC GLP-1 240 min 2,736±2,448 2,406±2,219 0.6 0.3
AUC GIP (pmol/l×min)
AUC GIP 240 min 12,313±3,840 14,585±5,905 0.04 0.004
IAUC GIP 240 min 8,857±4,354 10,921±5,184 0.06 0.02
AUC GLP-2 (pmol/l×min)
AUC GLP-2 240 min 5,280±1,040 5,812±1,738 0.1 0.4
IAUC GLP-2 240 min 1,698±1,461 1,221±2,015 0.3 0.08
AUC ISR (pmol/kg)
AUC ISR 240 minb 1,126±364 1,189±300 0.4 0.09
IAUC ISR 240 minb 683±212 706±206 0.6 0.4
AUC proinsulin/AUC insulin ratio
AUC proinsulin/AUC insulin 240 min 0.17±0.06 0.19±0.09 0.4 0.3
IAUC proinsulin/IAUC insulin 240 min 0.16±0.06 0.18±0.09 0.7 0.4
Data are means ± SD
a Calculated using a linear regression model, adjusting for fasting plasma glucose, BMI and age
b Data were log-transformed prior to analysis
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expression. Previously, impaired incretin effects among T
allele carriers have been demonstrated [19, 28]. Further-
more, reduced insulinotropic effects of both GLP-1 and GIP
among individuals with the rs7903146 risk allele based on a
hyperglycaemic clamp with co-infusion of GLP-1 and GIP
have been demonstrated [21]. Moreover, a recent study
among 18 non-diabetic individuals undergoing an OGTT
found a reduction in the incretin effect as well as a 50%
reduction in beta cell responsiveness to glucose [20]. Thus,
the increased level of GIP observed may be a response to
reduced beta cell responsiveness among TT allele carriers.
Interestingly, it has recently been suggested that GIP may
have a more important role in type 2 diabetes pathogenesis
than previously recognised, supported by observations that
patients undergoing bariatric surgery experience resolution
of type 2 diabetes as well as blunted postprandial GIP
secretion [47]. Thus, plasma GIP concentrations are not
decreased in type 2 diabetes, as observed for GLP-1, but
rather, GIP might be hypersecreted [48] while high-fat-fed
animals with decreased GIP actions are protected against
hyperglycaemia and impaired glucose tolerance [49].
Bearing this in mind, there is increasing evidence to
suggest that TCF7L2 T variants partly mediate their effect
through reduced production of GLP-1R and the GIP-R in
the pancreatic beta cell [27], possibly by alterations in
alternative splicing actions [10, 11]. Thus, we suggest that
one of the physiological consequences of having the
rs7903146 TT genotype is elevated levels of GIP, possibly
arising as a result of downregulated beta cell GIP-R.
Based on the established effect of the T allele on the
development of type 2 diabetes, it may be surprising that
we did not detect a more severe effect of having the
TCF7L2 T allele on measures of glucose homeostasis. This
may, however, be a consequence of including only 62
individuals. Furthermore, none of the presented data was
corrected for multiple testing. Even though some of the
tests are not independent, it should be kept in mind that this
multiple testing is prone to generating statistical type 1 errors.
In conclusion, our data indicate that multiple defects in
glucose homeostasis are present among glucose-tolerant
men carrying the high-risk TCF7L2 rs7903146 TT geno-
type. These individuals have increased levels of plasma
glucose in response to a meal challenge despite having
lower fasting plasma glucose levels, decreased processing
of proinsulin and elevated GIP secretion.
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